Abstract: The present relates to novel bioactive amphiphilic kanamycin compounds having the general formula of: where R may be a C4 to C20 branched or straight chained alkyl group or a substituted or unsubstituted aryl group. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating and preventing various fungal and bacterial diseases.

Abstract: The present invention relates to novel fungicidal compound including an aminoglycoside analog having certain substituents at the 6 position of ring III that exhibit improved antifungal activity but possess minimal antibacterial properties in combination with fungicidal azoles. The aminoglycoside compounds are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease.

Abstract: Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed.

Abstract: A fungicidal compound that includes an aminoglycoside, or salt thereof, having the formula: where R1 is a H; a C1 to C20 branched or straight alkyl; an unsubstituted phenyl; a substituted phenyl, wherein phenyl group may be C1 to C6 alkyl substituted; or a polyethylene glycol —(CH2CH2O)nR5— unit, wherein n=1 to 10 and R5?H or C1 to C20 branched or straight alkyl; R2 is a H; a C1 to C20 branched or straight alkyl; an unsubstituted phenyl; a substituted phenyl, wherein phenyl group may be C1 to C10 alkyl substituted; or a polyethylene glycol —(CH2CH2O)nR5— unit, wherein n=1 to 10 and R5?H or C1 to C20 branched or straight alkyl; R3 is H or OH; and R4 is OH or NH2.

Abstract: Methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin.

Abstract: Methods and materials for treating various diseases and medical conditions with meso-biliverdin compositions. In addition methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin are provided.

Abstract: Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed.

Abstract: Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed.

Abstract: The present invention relates to novel fungicidal compound including an aminoglycoside analog having certain substituents at the 6 position of ring III that exhibit improved antifungal activity but possess minimal antibacterial properties in combination with fungicidal azoles. The aminoglycoside compounds are analogues of kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease.

Abstract: Methods and materials for treating various diseases and medical conditions with meso-biliverdin compositions. In addition methods and materials for producing meso-biliverdin are provided where the methods include reacting phycocyanobilin with an amphoteric compound in a solvent to yield meso-biliverdin are provided.

Abstract: Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed.

Abstract: Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed.

Abstract: The present invention relates to novel aminoglycoside analogs having certain substituents at the 6 position of ring III which exhibit improved antifungal activity but possess minimal antibacterial properties. The compounds of the present invention are analogues of kanamycin B and kanamycin A. Also provided are methods of synthesizing and methods of using the compounds of the present invention. The compounds of the present invention are useful in treating or preventing fungal disease.

Abstract: Methods for producing biliverdin in a microorganism, methods for producing biliverdin from a non-animal source, cells for producing biliverdin and methods for producing cells for producing biliverdin are disclosed.

Abstract: A method for controlling infections caused by protozoans, such as Cryptosporidium parvum, Plasmodium falciparum, and Leishmania donovani. The method comprises using syringomycin-family lipodepsipeptides, preferably syringomycins such as syringomycin E, to control or prevent infections caused by protozoans. The method is directed to therapeutic treatment of mammals, such as humans, exposed to protozoans, and additionally as a prophylactic treatment in immunocompromised subjects at high risk for contracting protozoan infections.

Abstract: Lipodepsipeptides from Pseudomonas syringae pv. syringae were evaluated for antifungal activity. Specifically, the in vitro antifungal and fungicidal activities of three cyclic lipodepsinonapeptides syringomycin E, syringotoxin B, and syringostatin A against medically important isolates were evaluated using a standard broth microdilution susceptibility method. Erythrocyte toxicity was also evaluated. All three compounds showed broad antifungal activity and fungicidal action against most of the fungi tested.In addition, the present invention relates to a novel method for suppressing the immune system of mammals using cyclic lipodepsipeptides. The ability of cyclic lipodepsipeptides to suppress the immune system was evaluated in mitogen-induced lymphocytes. One cyclic lipodepsipeptide, syringomycin-E significantly inhibited mitogen--induced lymphocytes stimulation by pokeweed mitogen, phytohemagglutinin, and monoclonal antibodies to CD3.